A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

HPDCs-T immune therapy

HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;

Trial Locations (3)

200000

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

510630

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

650000

The second people's hospital of yunnan province, Kunming

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

collaborator

Second People's Hospital of Yunnan Province

OTHER

lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT01935635 - A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB | Biotech Hunter | Biotech Hunter